Access cutting-edge tardive dyskinesia treatment through this clinical trial at a research site in Cleveland. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Cleveland location
Preparing your pre-screening questions…
Access tardive dyskinesia specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related tardive dyskinesia treatment provided free
Check if you qualify for this tardive dyskinesia clinical trial in Cleveland, OH
No-Cost Study Care
Local to Cleveland
Convenient for OH residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The primary goal of this study is to investigate the efficacy of deutetrabenazine treatment of TD in this previously untreated patient population. Compare movement disorder deutetrabenazine treatment response in persons with IDD to response seen in patients without IDD treated with deutetrabenazine in other treatment settings (per literature review). Compare global deutetrabenazine treatment response with validated instruments. In addition, we plan to: * Assess the safety of deutetrabenazine in the treatment of TD in persons with IDD. * Assess change in Activities of Daily Living (ADLs) in persons with IDD and TD treated with deutetrabenazine, utilizing a validated ADL instrument. * Assess change in Quality of Life (QOL) in persons with IDD and TD treated with deutetrabenazine, utilizing a validated QOL instrument. * Assess caregiver burden with a validated caregiver burden instrument. In this study, 25 participants with IDD and TD will undergo Deutetrabenazine treatment for 24 weeks. The participants will be seen for a total of 5 visits: at baseline, and at follow up visits at 3 weeks, 6 weeks, 12 weeks, and 24 weeks. This study does not include a comparison group. Therefore, researchers will compare the response of the study participants to deutetrabenazine treatment with those from a previous reported work that resulted in the FDA approval of this medication. This will be an open-label, Phase 4 study.
Sponsor: University Hospitals Cleveland Medical Center
Yes, this clinical trial (NCT06997198) has an active research site in Cleveland, OH that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for tardive dyskinesia treatment options in Cleveland, OH, this clinical trial (NCT06997198) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Cleveland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced tardive dyskinesia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all tardive dyskinesia clinical trials near you to find additional studies recruiting in your area.
See all tardive dyskinesia clinical trials recruiting in Cleveland — not just this study.
Browse Tardive Dyskinesia Trials in Cleveland →